Cargando…

A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions

The success of applications of physiologically‐based pharmacokinetic (PBPK) modeling in drug development and drug labeling has triggered regulatory agencies to demand rigorous demonstration of the predictive capability of the specific PBPK platform for a particular intended application purpose. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frechen, Sebastian, Solodenko, Juri, Wendl, Thomas, Dallmann, André, Ince, Ibrahim, Lehr, Thorsten, Lippert, Jörg, Burghaus, Rolf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213412/ https://www.ncbi.nlm.nih.gov/pubmed/33946131 http://dx.doi.org/10.1002/psp4.12636

Ejemplares similares

A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim
por: Niederalt, Christoph, et al.
Publicado: (2017)

Predictive Performance of Physiology‐Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small‐Molecule Compounds in Children
por: Ince, Ibrahim, et al.
Publicado: (2021)

Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women
por: Dallmann, André, et al.
Publicado: (2018)

Open Systems Pharmacology Community—An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences
por: Lippert, Jörg, et al.
Publicado: (2019)

Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole
por: Türk, Denise, et al.
Publicado: (2019)

Physiologically‐Based Pharmacokinetic Models for CYP1A2 Drug–Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam
por: Britz, Hannah, et al.
Publicado: (2019)

Role of cytochrome P450 in drug interactions
por: Bibi, Zakia
Publicado: (2008)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
por: Wendl, Thomas, et al.
Publicado: (2021)

Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions
por: Johansson, Susanne, et al.
Publicado: (2017)

Retraction: Role of cytochrome P450 in drug interactions
por: Bibi, Zakia
Publicado: (2014)

Cytochrome P450 Enzymes and Drug Metabolism in Humans
por: Zhao, Mingzhe, et al.
Publicado: (2021)

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
por: Hanke, Nina, et al.
Publicado: (2018)

Talaromyces marneffei simA Encodes a Fungal Cytochrome P450 Essential for Survival in Macrophages
por: Boyce, Kylie J., et al.
Publicado: (2018)

Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo
por: Wang, Yiran, et al.
Publicado: (2020)

In Silico Prediction of Drug–Drug Interactions Mediated by Cytochrome P450 Isoforms
por: Dmitriev, Alexander V., et al.
Publicado: (2021)

Use of Drugs that Act on the Cytochrome P450 System in the Elderly
por: Cabrera, Marcos A S, et al.
Publicado: (2009)

Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children
por: Aka, Ida, et al.
Publicado: (2017)

Drug-drug interaction of acetaminophen and roxithromycin with the cocktail of cytochrome P450 and hepatotoxicity in rats
por: Liu, Xiang, et al.
Publicado: (2020)

Comparative Cytochrome P450 In Vitro Inhibition by Atypical Antipsychotic Drugs
por: Gervasini, Guillermo, et al.
Publicado: (2013)

An update on the role of intestinal cytochrome P450 enzymes in drug disposition
por: Xie, Fang, et al.
Publicado: (2016)

Effect of health foods on cytochrome P450-mediated drug metabolism
por: Sasaki, Takamitsu, et al.
Publicado: (2017)

A history of the roles of cytochrome P450 enzymes in the toxicity of drugs
por: Guengerich, F. Peter
Publicado: (2020)

Inflammatory signaling on cytochrome P450-mediated drug metabolism in hepatocytes
por: Wang, Xiaokang, et al.
Publicado: (2022)

Idiosyncratic Drug Induced Liver Injury, Cytochrome P450, Metabolic Risk Factors and Lipophilicity: Highlights and Controversies
por: Teschke, Rolf, et al.
Publicado: (2021)

African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development
por: Rajman, Iris, et al.
Publicado: (2017)

Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.
por: Meyer, U. A.
Publicado: (1996)

Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule
por: Mishra, Nitish K, et al.
Publicado: (2010)

Role of cytochrome P450 genotype in the steps toward personalized drug therapy
por: Cavallari, Larisa H, et al.
Publicado: (2011)

Cytochrome P450 enzyme mediated herbal drug interactions (Part 1)
por: Wanwimolruk, Sompon, et al.
Publicado: (2014)

Cytochrome P450 enzyme mediated herbal drug interactions (Part 2)
por: Wanwimolruk, Sompon, et al.
Publicado: (2014)

Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors
por: Dutkiewicz, Zbigniew, et al.
Publicado: (2018)

Computational methods and tools to predict cytochrome P450 metabolism for drug discovery
por: Tyzack, Jonathan D., et al.
Publicado: (2019)

Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450
por: Bukhdruker, Sergey, et al.
Publicado: (2020)

Inhibition of Cytochrome P450 Enzymes by Drugs—Molecular Basis and Practical Applications
por: Guengerich, F. Peter
Publicado: (2022)

Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design
por: Sun, Hao, et al.
Publicado: (2011)

Potential Cytochrome P450 Drug-Drug Interaction Among Adult and Adolescent Patients Undergoing Tonsillectomy
por: Nimmagadda, Sai, et al.
Publicado: (2020)

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein
por: Zahir, Hamim, et al.
Publicado: (2020)

Application of hepatic cytochrome b(5)/P450 reductase null (HBRN) mice to study the role of cytochrome b(5) in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine
por: Reed, Lindsay, et al.
Publicado: (2019)

Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan
por: Luong, Thu-Lan T., et al.
Publicado: (2021)

Clinically Significant Cytochrome P450-Mediated Drug-Drug Interactions in Children Admitted to Intensive Care Units
por: Li, Tong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4eh14i08sdc0n9qif2ktslcg6c